×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| Cohance Lifesciences Limited | 4966.8 | 525.7 | 4835.8 | 1.37 | 38,752 | 110.0 |
| Global Health Limited | 9052.95 | 1519.64 | 8821.56 | 5.65 | 37386 | 65.6 |
| Narayana Hrudayalaya Limited | 9595.77 | 873.71 | 9431.41 | 4.3 | 36472 | 46.1 |
SUVEN PHARMACEUTICALS LIMITED, with Security Code 543064, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 364.4 | 344.0 | 224.6 | 212.8 | 243.5 | 222.1 | 236.1 | 275.4 | 330.2 | 483.6 |
| Expenses | 189.8 | 174.1 | 127.3 | 144.7 | 171.4 | 139.1 | 135.1 | 159.9 | 262.9 | 379.4 |
| Operating Profit | 174.6 | 169.9 | 97.4 | 68.1 | 72.1 | 83.0 | 101.0 | 115.5 | 67.3 | 104.2 |
| OPM % | 47.92% | 49.38% | 43.34% | 32.02% | 29.63% | 37.39% | 42.79% | 41.93% | 20.37% | 21.55% |
| Other Income | 10.8 | 10.1 | 14.2 | 14.0 | 16.9 | 18.0 | 13.4 | 15.2 | 6.6 | 5.0 |
| Interest | 2.3 | 1.1 | 0.5 | 1.3 | 2.3 | 1.6 | 1.5 | 2.6 | 2.3 | 6.8 |
| Depreciation | 10.6 | 11.1 | 10.5 | 11.3 | 15.7 | 12.0 | 12.3 | 13.4 | 15.2 | 31.4 |
| Profit before tax | 172.5 | 167.6 | 100.6 | 69.5 | 71.1 | 87.4 | 100.7 | 114.6 | 56.4 | 79.1 |
| Tax % | -24.5% | -25.9% | -25.7% | -24.7% | -24.8% | -25.5% | -24.2% | -24.7% | -21.1% | 26% |
| Net Profit | 130.2 | 124.3 | 74.7 | 52.4 | 53.4 | 65.1 | 76.3 | 86.4 | 44.3 | 52.6 |
| EPS in Rs | 5.11 | 4.88 | 2.94 | 2.06 | 2.1 | 2.56 | 2.98 | 3.37 | 0 | 1.37 |
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 353.8 | 369.4 | 347.6 | 231.1 | 219.8 | 252.9 | 230.7 | 257.7 | 307.2 | 402.0 |
| Expenses | 207.1 | 200.3 | 180.6 | 133.1 | 154.7 | 179.6 | 150.8 | 153.7 | 189.5 | 328.4 |
| Operating Profit | 146.7 | 169.1 | 167.0 | 98.0 | 65.1 | 73.3 | 79.9 | 104.0 | 117.7 | 73.7 |
| OPM % | 41.47% | 45.78% | 48.04% | 42.4% | 29.64% | 29% | 34.64% | 40.36% | 38.32% | 18.32% |
| Other Income | 13.0 | 11.4 | 10.7 | 19.8 | 14.3 | 17.1 | 18.2 | 14.1 | 15.7 | 10.6 |
| Interest | 1.4 | 2.3 | 1.1 | 0.5 | 1.3 | 2.3 | 1.6 | 1.7 | 3.3 | 5.8 |
| Depreciation | 12.2 | 12.0 | 12.5 | 11.9 | 12.8 | 17.2 | 13.4 | 17.0 | 20.4 | 26.8 |
| Profit before tax | 146.1 | 166.2 | 163.9 | 105.4 | 65.5 | 70.9 | 83.1 | 99.5 | 109.7 | 51.7 |
| Tax % | -26.3% | -25.4% | -26.4% | -24.5% | -28.6% | -24.7% | 26.9% | 17.6% | 24.1% | -24.8% |
| Net Profit | 107.7 | 124.0 | 120.6 | 79.6 | 46.8 | 53.4 | 60.8 | 82.0 | 83.3 | 38.7 |
| EPS in Rs | 4.23 | 4.87 | 4.74 | 3.13 | 1.84 | 2.1 | 2.39 | 3.21 | 3.23 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 22% |
| 3 Years: | 1% |
| TTM: | -15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 20% |
| 3 Years: | -4% |
| TTM: | -26% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 46% |
| 3 Years: | 27% |
| 1 Year: | 71% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 23% |
| 3 Years: | 1% |
| TTM: | -10% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 20% |
| 3 Years: | -9% |
| TTM: | -25% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 46% |
| 3 Years: | 27% |
| 1 Year: | 71% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|